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Mitochondrial DNA (mtDNA) has been proposed to be involved in carcinogenesis and ageing. The mtDNA 4977 bp
deletion is one of the most frequently observed mtDNA mutations in human tissues and may play a role in breast
cancer (BC). The aim of this study was to investigate the frequency of mtDNA 4977 bp deletion in BC tissue and its
association with clinical factors.
We determined the presence of the 4977 bp common deletion in cancer and normal paired tissue samples from
106 Vietnamese patients with BC by sequencing PCR products.
The mtDNA 4977 bp deletion was significantly more frequent in normal tissue in comparison with paired cancer
tissue. Moreover, the incidence of the 4977 bp deletion in BC tissue was significantly higher in patients with
estrogen receptor (ER) positive as compared with ER negative BC tissue. Preliminary results showed, in cancerous
tissue, a significantly higher incidence of novel deletions in the group of patients with lymph node metastasis in
comparison with the patients with no lymph node metastasis.
We have found 4977 bp deletion in mtDNA to be a common event in BC and with special reference to ER positive
BC. In addition, the novel deletions were shown to be related to lymph node metastasis. Our finding may provide
complementary information in prediction of clinical outcome including metastasis, recurrence and survival of
patients with BC.
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The incidence of different cancers have increased both
in developed and in developing countries (Jemal et al.
2011). Breast cancer (BC) is one of the most common
cancers affecting women worldwide and the incidence is
rapidly rising in Asian countries. In Vietnam, the inci-
dence rate is 12 to 27per 100 000 (Anh & Duc 2002;
Le et al. 2002) while the incidence for women living
in Western countries is about 80 to 100 per 100 000
(Jemal et al. 2011).
The development of BC involves a progression through
intermediate states and processes leading to evolution to
carcinoma in situ, invasive carcinoma and metastasis.* Correspondence: andreas.matussek@rjl.se
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in any medium, provided the original work is pMutations in nuclear genes such as tumor-suppressor
genes and oncogenes, but also environmental exposures
contribute to the development of BC (McPherson et al.
2000; Polyak 2007; Schwartz et al. 2008). For example high
penetrance genes as BRCA1, BRCA2, PTEN and TP53
are responsible for the hereditary BC syndromes (Polyak
2007; Schwartz et al. 2008).
It is necessary to identify molecular markers to pre-
dict the progression, metastasis, recurrence and sur-
vival in BC. Hormone receptors status is used for
identifying a high-risk phenotype and to select suitable
regime for treatment (Banin Hirata et al. 2014). Other
tumor markers suggested useful in diagnostic proce-
dures and for prognosis in BC are expression of chemo-
kines, chemokine receptors and growth factors (Banin
Hirata et al. 2014).
Alongside the nuclear genome, the human cell con-
tains hundreds to several thousand copies of the 16 569s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ing 37 genes (Birch-Machin 2006; Penta et al. 2001).
Within cells the mtDNA has the capacity to form a mix-
ture of both wild-type and mutant mtDNA genotypes in
a state called heteroplasmy (Birch-Machin 2006; Penta
et al. 2001).
mtDNA has been proposed to be involved in carcino-
genesis and ageing (Birch-Machin 2006; Penta et al.
2001) and somatic mtDNA mutations have been re-
ported in various types of cancer, including BC (Penta
et al. 2001; Chen et al. 2011; Eshaghian et al. 2006;
Larman et al. 2012; Yadav & Chandra 2013; Ye et al.
2008). The main reason for its involvement in carcino-
genesis is probably that mtDNA has a high susceptibility
to undergo mutations due to its lack of histones, limited
repair mechanisms and a high rate of generation of re-
active oxygen species (Birch-Machin 2006; Penta et al.
2001). The mitochondrial 4977 bp deletion, also known
as the common deletion, is one of the most frequently
observed mtDNA mutations and has been associated
with different cancers (Chen et al. 2011; Eshaghian et al.
2006; Ye et al. 2008; Abnet et al. 2004; Dani et al. 2003).
The deletion occurs between nucleotides 8470 and 13
447 and spans five tRNA genes and seven genes encod-
ing subunits of cytochrome c oxidase, ATPases and com-
plex I (Chen et al. 2011; Ye et al. 2008). Moreover, the
deletion has a 13 bp direct repeat flanking the 5′- and
3′-end breakpoints at nucleotide position (np) 8470/8482
and np 13 447/13 459, respectively (Chen et al. 2011;
Ye et al. 2008).
In this study, we determined the frequency of the
4977 bp deletion in BC and corresponding non-cancerous
breast tissue samples from 106 Vietnamese patients
with BC.
Materials and methods
Patients and tissue specimens
This study comprised of 106 consecutive female patients
with BC, from northern Vietnam. Tissue specimens were
collected when the patients underwent surgical resec-









10398-reverse 5′-GATATGAGGTGTGAGCGATA-3′Vietnam. The mean age of the patients were 52 years
(range 24-89 years). Clinicopathological characteristics
from the patients were received from surgical and patho-
logical records. Tumor tissue and adjacent normal tissue
(about 5 cm from the tumor) from each patient were
excised and immediately frozen at 80°C until further
analysis.
Clinical and clinicopathologic classification and sta-
ging were determined according to the American
Joint Committee on Cancer (AJCC) criteria. The tumors
(invasive ductal carcinoma) were classified according to
TNM staging system and the distribution was: T1N0M0
(n = 8), T2N0M0 (n = 42), T3N0M0 (n = 5), T1N1M0
(n = 2), T1N2M0 (n = 2), T2N1M0 (n = 28), T2N2M0
(n = 3), T3N1M0 (n = 7), T3N2M0 (n = 1), T4N1M0 (6)
and T2N1M1 (n = 2).
Tumor grade of 79 patients was known: well differen-
tiated (n = 6), moderately differentiated (n = 56) and
poorly differentiated (n = 17). In 24 cases information
regarding positive and negative expression of estrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) in tumor
tissue, was available. ER + (n = 12), PR + (n = 5) and
HER2 + (n = 19). The study was approved by the local
Ethics Committee at the Vietnam National University,
Hanoi, Vietnam (2422/QD-KHCN) and all patients gave
their consent to participate in the study.
PCR assay
DNA was isolated from all BCs and paired normal tissues
by QIAamp DNA Mini kit (Qiagen, Hilden, Germany).
To screen for the mitochondrial 4977 deletion, a nested
PCR was developed to detect low levels of the deletion.
Two pairs of PCR primers were designed for the first
amplicon of 496 bp and the second amplicon of 381 bp
(Table 1). For the first amplicon, the primers were de-
signed to be distant enough to detect only mtDNAs
containing deletions. To assess the presence of mtDNA
and to detect heteroplasmy/homoplasmy regarding
4977 deletion, PCR primers were designed in the region
of the genes NADH dehydrogenase 1 (ND1) and ND3bp deletion analysis in this study
Position Product Note
3457-3476 433 bp ND1-region
3889-3870
8167-8187 496 bp First PCR
13639-13618
8196-8215 381 bp Second PCR
13553-13531
10307-10327 246 bp ND3-region
10552-10533
Figure 1 Agarose gel showing polymerase chain reaction (PCR) products from four breast cancer tissue/normal paired tissue.
Nested PCR (381 bp, lane 2/3, 4/5, 6/7, 8/9); 10398 (246 bp, lane 10/11, 12/13, 14/15, 16/17); mtDNA (433 bp, lane 18/19, 20/21, 22/23, 24/25) and
discovered novel deletions (700 bp, lane 2 and 9; 220 bp, lane 6). Lane 1, molecular marker.
Table 2 Mitochondrial DNA 4977-bp deletion in Vietnamese
patients with breast cancer
Prevalence of deletion (n)
Parameters No. of cases Negative Positive
Cancer tissue 106 33 73
Normal paired tissue 106 17 89
Stage*
T1N0M0 8 2 6
T2N0M0 42 12 30
T3N0M0 5 2 3
T1N1M0 2 1 1
T1N2M0 2 2 0
T2N1M0 28 6 22
T2N2M0 3 2 1
T3N1M0 7 2 5
T3N2M0 1 0 1
T4N1M0 6 3 3
T2N1M1 2 1 1
*Cancer tissue.
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(Table 1).
Except for the second PCR run for 4977 deletion,
DNA was amplified in a total volume of 12.5 μl contain-
ing 0.2 μM of each primer (TIB Molbiol, Berlin,
Germany), 1.8 mM MgCl2, 200 μM of each deoxynu-
cleotide triphosphate, 0.04 units Taq DNA polymer-
ase and reaction buffer [20 mM Tris-HCl (pH 8.3),
20 mM KCl, 5 mM (NH4)2SO4] (Fermentas, Burlington,
Canada). Amplification was done with an initial denatur-
ation at 95°C for 4 min followed by 35 cycles at 92°C for
30 s (denaturation), 54°C for 30 s (annealing), 72°C for
45 s (extension) and final elongation at 72°C for 10 min.
For the second PCR run regarding the 4977 deletion, the
conditions were the same as above except that an anneal-
ing temperature of 60°C and a total number of 32 cycles
was used. The amplified PCR products were visualized by
UV-illumination on 2% agarose gel containing Gel Red
(Biotium, Inc., Hayward, CA). The band reflecting the
4977 common deletion and all the other bands that were
obtained at different levels on the gel were purified with
Gel Extraction kits (Qiagen, Hilden, Germany), followed by
commercial sequencing (GATC Biotech, Köln, Germany).
Statistical analysis
Differences in the rate of mtDNA deletions were an-
alyzed using the Chi-square test. Statistical analyses
were performed using SPSS for Windows computer
package (IBM SPSS Statistics, 2012, version 19; SPSS
Inc., Chicago, IL). Results were considered significant
at p < 0.05.
Results
Frequency of mtDNA 4977 bp deletion in patients
with BC
All samples showed clear bands with mtDNA and 10398
primers representing 433 bp and 246 bp respectively
(Figure 1). In lanes 2, 6 and 9 (Figure 1), three novel de-
letions were detected (700, 220 and 700 bp, respectively)
which were confirmed by sequencing. For the 4977 bpdeletion, represented by bands 381 bp, we defined two
types of signals by nested PCR: negative and positive
clear band (Table 2). The deletion was detected in 68.8%
(73/106) of cancerous tissues and 84.0% (89/106) of nor-
mal paired tissues (Table 2) (p < 0.01).
With regard to disease stage, the patients were divided
into two sub-groups, one with no metastasis to lymph
node or other organs (T1-3, N0, M0) and one with
spread (T1-4, N1-3, M0-1). However, no significant dif-
ference was seen with respect to the frequency of
4977 bp deletion. Nor were tumor grade or age associ-
ated with the 4977 bp deletion (data not shown).
We found a significantly (p < 0.01) higher rate of the
4977 bp deletion in patients with ER+, 91.2% (11/12)
compared with ER−, 41.2% (5/12). Neither PR nor HER2
showed statistically significant correlation to the pres-
ence of 4977 bp deletion.
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After nested PCR, we detected different bands in
addition to the 381 bp which represents the 4977 bp de-
letion. The bands that were both larger and smaller than
381 bp were purified, sequenced and the corresponding
deletions were analyzed using the program BLASTn
(Altschul et al. 1990). The deletions were checkedTable 3 Novel mtDNA deletion (n = 36) detected in breast can





































D, direct repeat; NR, no repeat; nt, nucleotide; I, indirect repeat.against the MITOMAP database (MITOMAP 2013) and
other possible reference sources, with the consequence
that we characterize our findings as novel deletions.
Tables 3 and 4 summarize the novel deletions in tumor
and normal tissue with information about breakpoints,
deletion size, repeat location and type, respectively. We
found 36 novel deletions in the tumor tissue distributedcer tissue





































Table 4 Novel mtDNA deletion (n = 30) detected in breast normal tissue
Patient code Deletion junction (nt:nt) Deletion size (bp) Repeat location (nt) Repeat type
4 8251:13414 5162 8244-8250/13409-13415 D, 7/7
6 8257:13447 5189 8257/13446 D, 1/1
8 8226:13459 5232 8225-8227/13459-13461 D, 3/3
9 8326:13480 5153 8327-8328/13479-13480 D, 2/2
11 8332:13210 4877 - NR
19 8313:13522 5208 8314-8316/13521-13523 D, 3/3
19 8300:13206 4905 8299-8300/13204-13205 D, 2/2
20 8263:13461 5197 8259-8263/13457-13461 I, 5/5
20 8231:13328 5096 8228-8231/13328-13332 D, 4/5
24 8564:13334 4769 8560-8564/13328-13332 D, 5/5
28 8305:13533 5227 8304-8305/13531-13532 D, 2/2
32 8256:13313 5056 8254-8257/13309-13312 I, 4/4
38 8435:13474 5038 8434-8435/13472-13473 D, 2/2
41 8396:13466 5069 8395-8396/13464-13465 D, 2/2
43 8299:13463 5163 8294-8299/13457-13462 D, 5/6
50 8234:13286 5051 8231-8234/13283-13285 D, 3/4
52 8297:13428 5130 8295-8297/13425-13427 D, 2/3
52 88801:13462 4660 8787-8801/13448-13461 D, 13/15
59 8355:13440 5084 8343-8355/13428-13439 D, 11/13
61 8216:13396 5179 - NR
65 8425:13297 4871 8421-8425/13291-13296 I, 5/6
67 8362:13465 5102 8363-8364/13465-13466 I, 2/2
79 8492:13529 5036 8491-8492/13527-13528 D, 2/2
79 8215:13117 4901 8214-8215/13115-13116 D, 2/2
88 9160:12966 3805 9149-9160/12954-12965 D, 12/12
92 8556:13170 4613 8553-8556/13166-13169 D, 3/4
101 8349:13421 5071 8348-8349/13419-13420 D, 2/2
103 8312:13467 5154 8313/13466 D, 1/1
106 8259:12994 4734 - NR
107 8534:13399 4864 8526-8534/13390-13398 D, 8/9
D, direct repeat; NR, no repeat; nt, nucleotide; I, indirect repeat.
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tissue spread over 26 patients.
A number of patients with at least one novel deletion
in the cancerous tissue were 12 with no involved lymph
nodes (N0) and in 21 with involved lymph nodes (N1-2).
Moreover, we observed, in cancerous tissue, a signifi-
cantly (p < 0.05) higher rate, 41.2% (21/51), of the novel
deletions in the group of patients defined as N1-2 in
comparison with 21.8% (12/55), in the group defined as
N0. However, this result is not consistent with good stat-
istical power which has a value around 0.6. There were
no associations between the novel deletions and other
clinical characteristics and no associations in the normal
tissue (data not shown).Observed novel mtDNA single nucleotide variants
Fifteen novel mtDNA single nucleotide variants were
identified in the region sequenced and resident in the
novel deletions reported here (Table 5). These were not
linked to any clinical parameter available in this study
(data not shown).
Discussion
The mitochondrial 4977 bp deletion has been found in
tissues from several tumor types and adjacent normal
tissues (Penta et al. 2001; Chen et al. 2011; Ye et al.
2008; Abnet et al. 2004; Dai et al. 2006). Recently, re-
duced mitochondrial mutagenesis in colorectal cancer
has been shown, as well as a higher frequency of mtDNA
Table 5 Novel mtDNA single nucleotide variants detected
in breast cancer and normal tissue








61 Cancer C8472A, A13519C
68 Cancer A13395G
77 Cancer C8270T, C13503T
86 Cancer G13480T, T8317G
104 Cancer T13488C
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et al. 2012). In the present study, the mtDNA 4977 bp de-
letion was found at a significantly higher frequency in nor-
mal tissue in comparison with paired cancer tissue in
Vietnamese BC patients. We also observed a pervading
heteroplasmy in the tissues. Our results are consistent with
a previous study showing decreased proportions of the
mtDNA 4977 bp deletion in various cancer types com-
pared with adjacent normal tissue, such as breast (Ye et al.
2008), lung (Dai et al. 2006), gastric (Wu et al. 2005) and
colorectal cancer (Dimberg et al. 2014). One explanation of
this phenomenon might be a dilution of the mtDNA
4977 bp deletion in tumor tissue as a result of clonal ex-
pansion during cancer progression or that cells harbouring
this deletion are eliminated by apoptosis (Wu et al. 2005).
Moreover, the mtDNA 4977 bp deletion might confer a
metabolic disadvantage to proliferating cells and thus
is selected out in the highly proliferative tumor tissue
(Wu et al. 2005).
Testing the tumor for hormonal receptors is a stand-
ard part of a BC diagnosis. In general BC with positive
hormonal receptor status tends to be more aggressive
and fast growing. Moreover, the receptor status pre-
dicts the treatment response and thus will influence
the treatment regimen (Goldhirsch et al. 2009). In the
present study, we found that the incidence of the
4977 bp deletion in BC tissue is significantly higher in
the patients with ER positive as compared with ER
negative patients. It has been reported that p53 plays a
role in the maintenance of mtDNA integrity by con-
trolling replication and repair through interaction with
DNA pol gamma (Achanta et al. 2005). A study dem-
onstrated that ER binds to p53 on the p53 target gene
and represses p53 mediated transcriptional activation
(Konduri et al. 2010) and may thus explain that 4977 bpdeletion seems to be more prevalent among ER positive
patients.
In addition to the 4977 bp deletion, we discovered
novel large scale deletions, 36 in cancerous and 30 in
normal tissue. Moreover, 15 novel mtDNA single nu-
cleotide variants were identified within the region se-
quenced and resident in the novel deletions reported
here.
Interestingly, we observed, in cancerous tissue, a sig-
nificantly higher incidence of the novel deletions in
the group of patients with lymph node metastasis in
comparison with the patients with no lymph node me-
tastasis. However, this result is preliminary because of
insufficient number of patients. It is possible that our
novel deletions are involved in the mediation of tumor
progression. However, our finding does not provide an-
swers as to whether mtDNA alterations are contributing
factors to carcinogenesis or whether they simply arise as
part of secondary effects in cancer progression. Whether
our detected novel deletions have an impact on cancer
development or not requires further investigation. Stud-
ies have shown that a reduced mtDNA content is associ-
ated with higher histological grade in BC (Yadav &
Chandra 2013) while other studies failed to demonstrate
any correlation with tumor grade or metastasis (Yadav &
Chandra 2013; Mambo et al. 2005). In the future, it
would be of interest to investigate this type of correl-
ation in our group with increased number of patients.
To our knowledge, this is the first time that mtDNA
alteration in BC tissue and paired normal tissue has
been analyzed in Vietnamese patients. We have focused
on identification of the 4977 bp deletion but also on
characterization of novel mutations. The results about
the novel mutations must be confirmed by expanding
the investigation. Studies using increased sample size are
required to determine the clinicopathologic role of the
sequence variation of mtDNA in BC. Our finding may
provide complementary information in additional studies
to define the importance of the mtDNA deletions found
in prediction of clinical outcome including metastasis,
recurrence and survival of patients with BC.
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